Table of Contents
- Why doesn't a distributor relationship guarantee access to a value analysis committee?
- What is a value analysis committee, and who sits on it?
- Why do most medtech companies never build outbound to reach VAC members directly?
- Is distributor-led access actually working, or just familiar?
- How do you build outbound to a value analysis committee without disrupting your distributor?
- The VAC Access Framework: Five Steps
- What does the data say about healthcare buyer responsiveness to direct outbound?
- Conclusion
- Key Terms Glossary
- Related reading
Most medical device companies still sell into hospitals the way the industry has for decades: through a distributor or manufacturer's rep who owns the relationship with the account. That model works, but it has a structural weakness few device companies ever address. Medtech outbound to value analysis committees does not exist in most sales organisations, because the assumption is that the distributor's rep handles that conversation. The result is that the company selling the device has almost no direct visibility into, or influence over, the committee that actually approves the purchase.
This is not an argument for replacing distributors. It is an argument for building a second, direct channel to the value analysis committee alongside them, so the company that makes the device is not entirely dependent on someone else's relationship for its own new-account growth.
Why doesn't a distributor relationship guarantee access to a value analysis committee?
A distributor relationship guarantees a route to market, not a voice in the room where the purchase gets decided. The rep who calls on a hospital typically represents a portfolio of manufacturers, not one device exclusively, and has limited incentive to push hard for any single product line ahead of the others in the bag. The device manufacturer, meanwhile, has no direct line to the clinical, financial, and supply-chain stakeholders who sit on the value analysis committee and who ultimately decide whether the product gets adopted, and at what volume.
The structural gap this creates is simple: the manufacturer with the most to gain from a specific approval has the least direct influence over the people making it.
What is a value analysis committee, and who sits on it?
A value analysis committee (VAC) is the cross-functional hospital body that reviews new medical products and equipment against clinical evidence, cost, and existing standardisation agreements before a purchase proceeds. It typically sits above individual department requests and below final capital budget approval for larger purchases.
| Role | Primary concern | Authority level |
|---|---|---|
| VAC Chair / Value Analysis Director | Evidence quality, standardisation, committee process | Chairs the review; strong gatekeeping authority |
| Materials Management / Supply Chain Director | Contract terms, group purchasing organization alignment, total cost of ownership | Approval authority on sourcing and contracting |
| Physician Champion | Clinical outcomes, workflow fit, patient safety | High influence; often required to sponsor a new product |
| Nursing / Clinical Service Line Lead | Day-to-day usability, training burden, staff adoption | Strong influence on committee recommendation |
| Finance / Capital Planning | Budget availability, return on capital, contract structure | Approval authority above a defined spend threshold |
Understanding this committee structure is the starting point for medtech outbound to value analysis committees, because a message aimed only at a purchasing manager will never reach the physician champion or the value analysis director who actually shapes the recommendation.
Why do most medtech companies never build outbound to reach VAC members directly?
Most medtech companies never build this outbound because the distributor relationship feels like it already covers hospital access, and going around it looks like a channel conflict risk. That reasoning treats "a channel exists" and "the right stakeholders are being reached" as the same thing, and they are not.
A distributor rep managing dozens of accounts and a wide product portfolio cannot realistically build a deep relationship with every physician champion and value analysis director across every hospital system. A manufacturer that builds its own outbound system to reach these stakeholders directly, in parallel with the distributor relationship rather than instead of it, closes that gap without disrupting the existing channel.
Is distributor-led access actually working, or just familiar?
Distributor-led access is often mistaken for a working system simply because it is the established one, not because it is being measured against a direct alternative.
| Dimension | Distributor-led access only | Direct outbound to the VAC |
|---|---|---|
| Speed to first hospital conversation | Slow; depends on rep's existing priorities and portfolio | Fast; manufacturer controls timing and account selection |
| Message control | Diluted across the rep's full product portfolio | Full control of clinical and evidence framing |
| Account selection precision | Broad, rep-driven territory coverage | Targeted at accounts matching a specific clinical profile |
| Visibility into committee decision-making | Limited; manufacturer hears outcomes, not deliberation | Direct; manufacturer builds relationships with committee members |
| Scalability into new hospital systems | Constrained by distributor's existing footprint | Independent of any single distributor's territory |
Neither column is complete on its own. The manufacturers with the most consistent new-account growth run both at once.
How do you build outbound to a value analysis committee without disrupting your distributor?
The most reliable approach positions direct outbound as evidence generation and relationship-building that supports the distributor's sale, not as a competing sales motion. Outreach to a physician champion focused on clinical evidence and outcomes data, or to a value analysis director focused on standardisation and process, builds internal advocacy that makes the distributor's job easier when the formal proposal reaches the committee.
The sequence typically opens with the physician champion, since clinical credibility travels further inside a VAC than a commercial pitch, and closes with a structured introduction to the value analysis director once clinical interest is established.
The VAC Access Framework: Five Steps
- Identify target hospital systems by clinical profile. Prioritise accounts where the patient population, procedure volume, or existing equipment base creates a clear clinical case for the product, rather than working a generic territory list.
- Map the committee for each target account. Identify the value analysis chair, the physician champion most likely to sponsor the category, the materials management contact, and the relevant nursing or service line lead.
- Open with the physician champion on clinical evidence. The first message should reference specific clinical data, a comparable deployment, or a relevant outcomes study, not commercial terms or pricing.
- Build the clinical case before any commercial conversation. A short call establishes relevance and surfaces the standardisation agreements, budget cycle, and existing supplier relationships that will shape how the value analysis committee reviews the product.
- Coordinate, do not compete, with the distributor. Once clinical interest is established, loop in the distributor rep for the formal proposal and contracting stage. The manufacturer's direct outbound has done the work of building internal advocacy; the distributor still closes the commercial relationship.
What does the data say about healthcare buyer responsiveness to direct outbound?
Across the campaigns Danish Lead Co. has managed in the last 90 days, hospitals and health care produced more positive replies than any other single industry segment we track, ahead of every manufacturing category in our data, with medical equipment manufacturing and medical practices also placing among the top ten most responsive industries. That pattern is consistent with what the VAC access framework predicts: healthcare buyers respond to precision and clinical relevance, not volume, and a well-targeted direct approach reaches them at a rate that a portfolio-wide distributor motion structurally cannot match. More detail on how this shows up across sectors is available in our case studies.
A comparable pattern shows up outside healthcare too. A manufacturer working with Danish Lead Co. booked 94 qualified buyer conversations in under two months by mapping a technical buying committee directly, rather than relying solely on an existing distributor network, which is the same structural move medtech outbound to value analysis committees makes for hospital accounts.
Conclusion
A distributor relationship is a route to market. It is not the same thing as a direct line to the physicians, value analysis directors, and materials managers who decide whether a new device gets adopted. Medtech outbound to value analysis committees closes that gap: a manufacturer that builds clinical-evidence-led relationships with committee stakeholders directly, alongside its existing distributor channel, has more control over its own new-account growth than one that waits entirely on someone else's relationship.
If you are building or refining this kind of system for your device or product line, book a strategy call to discuss your clinical evidence, target accounts, and existing channel structure. You can also read about our approach to outbound systems and view our services, or see how we support healthtech companies more broadly.
